The final trial results showed that younger and older patients with FLT3-ITD-mutated AML benefitted from adding midostaurin to intensive chemotherapy.
The large, population-based study showed prevalence in 40 years+ patients. Approximately 1 out of 3 smouldering MM patients may progress towards MM.
Teclistamab was safe and efficacious in relapsed/refractory multiple myeloma patients. Phase 1/2 trial showed durable and deepening responses.
CHIP was related to decreased risk of AD and its neuropathological changes. Mutated haematopoietic stem cells were detected in the brains of CHIP carriers.
A quizartinib, venetoclax and decitabine combo was highly active in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukaemia.
A JAK2V617F variant with an allele frequency of over 50% is associated with a higher risk of venous thrombosis in patients with polycythaemia vera (PV).
Cladribine plus low-dose cytarabine plus venetoclax alternated with 5-azacytidine plus venetoclax showed encouraging efficacy in newly diagnosed AML patients.
Treatment with fitusiran for prophylaxis resulted in a lower rate of bleeding events and improved health quality of life in haemophilia A or B patients with inhibitors.
Significant disparities in health outcomes were observed across race, ethnicity, and socioeconomic status (SES) in patients with acute lymphoblastic leukaemia (ALL).
CPX-351 therapy did not result in different overall survival (OS) outcomes or response rates than venetoclax plus HMA therapy in patients with acute myeloid leukaemia (AML) between 60 and 75 years of age.
The combination regimen of low-dose tacrolimus plus high-dose dexamethasone provides benefits over high-dose dexamethasone monotherapy in patients with immune thrombocytopenia (ITP), promising first-line treatment for patients with ITP.
The dual therapy demonstrated durable and deep responses in heavily pre-treated patients with refractory MM. The combination regimen was tolerable and did not show overlapping toxicity. It is therefore a promising option for treating patients with MM.
Combination therapy of eprenetapopt plus azacytidine showed efficacy and safety in patients with TP53-mutant myelodysplastic syndrome and oligoblastic acute myeloid leukaemia.
Immune-mediated inflammatory disease treated with a TNFα inhibitor had a 2-fold increased risk of new-onset psoriasis compared with conventional therapy.
Pooled safety analyses of 2 phase 3 trials revealed similar tolerability of the IL-17A inhibitor secukinumab in children and adolescents with moderate-to-severe plaque psoriasis.
Digital health apps offer those affected by depression the possibility of supporting psychotherapy. Dr. sc. hm. Gwendolyn Mayer explains what these apps are about, who they are suitable for and how effective they are.
When a person is at the end of their life, it means change. At Heidelberg University Hospital, a team of therapists works with the concept of Dignity Therapy according to Chochinov and expands it to include the aspect of couple relationships.
The number of mental illnesses worldwide is growing - and with it the need for good therapies. What is the benefit of treating depression and anxiety with virtual reality? Researchers from New Zealand have evaluated studies.
What does the Covid-19 pandemic do to people psychologically? This questions was addressed in a lecture at the University Hospital Jena, Germany.
Most rheumatism drugs can be used safely in SARS-CoV-2 infections. Some even seem to protect against severe cases, but individual drugs were associated with a complicated disease path.